Taustine Eye Center

A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide 11Ms. Clineschmidt, Dr. Adamsons, Dr. Snyder, and Dr. Reines are employees of Merck & Co., Inc., the manufacturer of the dorzolamide-timolol combination. The other authors have no proprietary interest in the dorzolamide-timolol combination or in Merck.

Coleen M. Clineschmidt, Robert Williams, Ellen Snyder et al. · Ophthalmology · 1998 · 140 citations

Dr. Snyder, Clinical Therapeutic, Systemic Treatment +7

Ocular Hypotensive Effect of the Rho Kinase Inhibitor AR-12286 in Patients With Glaucoma and Ocular Hypertension

Robert D. Williams, Gary D. Novack, Thomas van Haarlem et al. · American Journal of Ophthalmology · 2011 · 130 citations

Hypertension, Ocular Disease, Ophthalmology +7

Brimonidine and Timolol Fixed-Combination Therapy Versus Monotherapy: A 3-Month Randomized Trial in Patients with Glaucoma or Ocular Hypertension

E. Randy Craven, Thomas R. Walters, Robert D. Williams et al. · Journal of Ocular Pharmacology and Therapeutics · 2005 · 79 citations

Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost

Robert D. Williams · Advances in Therapy · 2002 · 53 citations

Hypertension, Urology, Ocular Disease +5

Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4

Robert D. Williams, John Cohen, Ronald L. Gross et al. · British Journal of Ophthalmology · 2008 · 51 citations